HBV mutation literature information.


  Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
 PMID: 35359734       2022       Frontiers in microbiology
Table: T184L


  Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes.
 PMID: 34319801       2021       Journal of clinical microbiology
Abstract: We developed a novel real-time PCR assay that simultaneously evaluates 11 major nucleos(t)ide antiviral (NA) drug resistance mutations (mt) in chronic hepatitis B patients (CHB), including L180M, M204I/V, and V207M (lamivudine [LMV] resistance), N/H238A/T (adefovir [ADF] resistance), which are circulating in Vietnam; and T184G/L, S202I, and M250V (entecavir [ETV] resistance) and A194T (tenofovir resistance), which have been recently reported in several studies across the globe.


  Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR.
 PMID: 34007795       2021       Journal of clinical and translational hepatology
Table: T184L


  Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.
 PMID: 33562603       2021       International journal of molecular sciences
Discussion: Nevertheless, some recent studies have shown that rtS78T/sC69*, rtS106C/rtH126Y/rtD134E/rtL269I, and rtL180M/T184L/M204V/rtA200V are related to TDF resistance.


  Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance.
 PMID: 31498528       2020       Liver international
Abstract: CONCLUSION: An rtL180M/T184L/A200V/M204V mutant with moderate resistance to TDF monotherapy was selected during sequential nucleoside analogue (NA) treatment in a stepwise manner.
Abstract: In v
Abstract: METHODS AND RESULTS: Here, we report viral rebound in a patient with chronic hepatitis B who underwent TDF monotherapy and harboured a quadruple mutant consisting of classic entecavir (ETV)-resistance mutations (rtL180M/T184L/M204V) together with an rtA200V mutation in the reverse transcriptase gene.


  Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization.
 PMID: 32216026       2020       Liver international
Abstract: Additionally, the ETV resistance mutations rtT184A/L, rtS202G and rtM250V were found among three patients.


  COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B.
 PMID: 32708399       2020       Diagnostics (Basel, Switzerland)
Method: All sequences with completely replaced mt were further determined based on an HBV-drug resistance interpretation online tool of Max Planck Institute for Informatics for classical mt, e.g., rtL180M, rtA181V/T
Method: Primers for PCR amplification of nucleotides (nt) 532-929, corresponding to the B, C, D, and E domains and containing major NA-drug resistance mt in HBV RT such as rtV173L, rtL180M, rtA181V/T, rtT184G/L, rtA194T, rtS202I/G, rtM204I/V, rtN236T, and rtM250I/V, were designed as follows.


  Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients.
 PMID: 33124952       2020       Emerging microbes & infections
Figure: Small red arrows reflect the site of primary and secondary resistance mutations, from bottom to top: rtL180M, rtA181V/T/I, rtT184S/L, rtM204V/I, rtN236T/I.


  Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations.
 PMID: 32994690       2020       World journal of gastroenterology
Figure: M1, sA159V; M2, rtM204I; M3, sA159V+rtM204I; M4,
Discussion: The sA159V+rtL180M+rtT184L+rtM204V mutant is probably derived from sA159V+rtL180M+rtM204V as an adaptation to ETV pressure.


  [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
 PMID: 31130119       2019       Mikrobiyoloji bulteni
Abstract: Primary/secondary drug mutations (rtM204I/V, rtI169S, rtL180M, rtT184L, rtA194V, rtM204I/rtL91I, rtQ149K, rtQ215H/S, rtN238D) were detected in 38 (45.2%) of the patients.



Browser Board

 Co-occurred Entities




   Filtrator